Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Ruth Ladenstein,Ulrike Pötschger,Dominique Valteau-Couanet,Roberto Luksch,Victoria Castel,Shifra Ash,Geneviève Laureys,Penelope Brock,Jean Marie Michon,Cormac Owens,Toby Trahair,Godfrey Chi Fung Chan,Ellen Ruud,Henrik Schroeder,Maja Beck-Popovic,Guenter Schreier,Hans Loibner,Peter Ambros,Keith Holmes,Maria Rita Castellani,Mark N. Gaze,Alberto Garaventa,Andrew D.J. Pearson,Holger N. Lode,Ladenstein,Pötschger,Valteau-Couanet,Luksch,Castel,Ash,Laureys,Brock,Michon,Owens,Trahair,Chi Fung Chan,Ruud,Schroeder,Beck-Popovic,Schreier,Loibner,Ambros,Holmes,Castellani,Gaze,Garaventa,Pearson,Lode
DOI: https://doi.org/10.3390/cancers12020309
2020-01-28
Cancers
Abstract:To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard induction and high-dose therapy (HDT) with autologous stem cell rescue (ASCR); the local control comprised surgery and radiotherapy to the primary tumour site, followed by isotretinoin. A landmark timepoint of 109 days, resulting from the median time between ASCR and initiation of immunotherapy, was used to define patients’ eligibility in the pre-immunotherapy analysis cohort. Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2–8.2 years) for 844 eligible patients balanced for risk factors, such as age, sex, stage 4, MYCN amplification and response prior to HDT. The five-year event-free and overall survival (95% confidence interval (CI) of 466 patients not receiving immunotherapy was 42% (38–47%) and 50% (46–55%) but was 57% (51–62%) and 64% (59–69%) for 378 patients receiving immunotherapy (p 1 metastatic compartment at diagnosis (p < 0.001, HR 2.665) as risk factors for relapse or progression. Results suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts applied in HR-NBL1/SIOPEN.
oncology